Alimta Mesothelioma

The World Market For Cancer Therapeutics And Biotherapeutics, 3Rd. Edition

Worldwide cancer affects more than 10 million people each year. This number is expected to increase by 2.4% by 2020 to 14 million each year. Worldwide approximately 22 million people are living with cancer and nearly 7 million people die. The most common cancers affecting the world include lung, breast, colon/rectum, stomach, liver, prostate, cervical, [...]

The Cancer Market Outlook To 2014: Competitive Landscape, Market Size, Pipeline Analysis And Growth Opportunities Report

In the current decade, oncology has been one of the most important growth segments among the pharmaceutical markets with a major focus on targeted agents (drug treatments developed to preferentially target those signaling pathways that are disregulated in tumors). Most innovation in oncology over the past 10 years has been driven by scientific advances, particularly [...]

The Cancer Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities—Aarkstore Enterprise

Aarkstore announce a new report  “The Cancer Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities” through its vast collection of market research report. The Cancer Market Outlook to 2013 Competitive landscape, pipeline analysis and growth opportunities The market for cancer treatments is one of the largest and fastest growing areas in [...]

Lung Cancer Therapeutics Market Outlook And Pipeline Analysis

Lung Cancer Therapeutics Market Outlook and Pipeline Analysis  With over 50% of all non-small cell lung cancer (NSCLC) patients diagnosed at the advanced stages of the disease, and 95% of all small-cell lung cancer (SCLC) patients unsuitable for surgical resection, drug therapy plays a vital role in the management of lung cancer. Such high level [...]

The Cancer Market Outlook To 2014: Competitive Landscape, Market Size, Pipeline Analysis And Growth Opportunities

Most innovation in oncology over the past 10 years has been driven by scientific advances, particularly in genomics, transcriptomics and proteomics. In the current environment, the successful oncology players of the future will be those that can anticipate protocol evolution and design the most relevant clinical trials. In recent years, biotech companies have fuelled [...]